Evaluation of 99mTc-ZIGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression

Amino Acids

Volumn 47, Issue 2, 2015, Pages 303-315

  Mitran, Bogdan ^a   Altai, Mohamed ^a   Hofström, Camilla ^b   Honarvar, Hadis ^a   Sandström, Mattias ^a   Orlova, Anna ^a   Tolmachev, Vladimir ^a   Gräslund, Torbjörn ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

99mTc; Affibody molecule; Biodistribution; IGF 1R; Peptide based chelator

Indexed keywords

RADIOPHARMACEUTICAL AGENT; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; Z SOMATOMEDIN C RECEPTOR 4551 GLYCYLGLYCYLGLYCYLCYSTEINE TC 99M; HYBRID PROTEIN; IGF1R PROTEIN, HUMAN; SOMATOMEDIN RECEPTOR; TECHNETIUM; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST TUMOR; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; METABOLISM; NUDE MOUSE; PROSTATE TUMOR; SCINTISCANNING; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOMEDIN; RECOMBINANT FUSION PROTEINS; TECHNETIUM;

EID: 84922105067     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-014-1859-z     Document Type: Article

References (48)

1. Ahlgren S, Tolmachev V (2010) Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 11:581-589
2. Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B, Widmark O, Fant G, Feldwisch J, Tolmachev V (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem 19:235-243
3. Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE, Feldwisch J, Orlova A, Tolmachev V (2009) Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med 50:781-789
4. Ahlgren S, Andersson K, Tolmachev V (2010) Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine. Nucl Med Biol 37:539-546
5. Baserga R (2009) The insulin receptor substrate-1: a biomarker for cancer? Exp Cell Res 315:727-732
6. Björkelund H, Gedda L, Andersson K (2011) Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context. PLoS One 31(6):e16536
7. Carden CP, Molife LR, de Bono JS (2009) Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor. Mol Cancer Ther 8:2077-2078
8. Chitnis MM, Yuen JSP, Protheroe AS, Pollak M, Macaulay VM (2008) The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14:6364-6370
9. Dearth RK, Cui X, Kim HJ, Hadsell DL, Lee AV (2007) Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 6:705-713
10. Fleuren ED, Versleijen-Jonkers YM, van de Luijtgaarden AC, Molkenboer-Kuenen JD, Heskamp S, Roeffen MH, van Laarhoven HW, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WT (2011) Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res 17:7693-7703
11. 2-R1507 fragments in Ewing sarcomas. Eur J Cancer 49:2851-2858
12. Guvakova MA, Surmacz E (1997) Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res 231:149-162
13. Haisa M (2013) The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer. J Int Med Res 41:253-264
14. Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, Karl RC, Coppola D (1999) Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 30:1128-1133
15. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM (2002) Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62:2942-2950
16. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Franssen GM, Versleijen-Jonkers YM, Oyen WJ, van der Graaf WT, Boerman OC (2010) ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med 51:1565-1572
17. 2 and Fab fragments of the monoclonal antibody R1507. Mol Pharm 9:2314-2321
18. Hofström C, Orlova A, Altai M, Wångsell F, Gräslund T, Tolmachev V (2011) The use of a HEHEHE-purification tag improves biodistribution of Affibody molecules site-specifically labeled with 99mTc, 111In and 125I compared to a hexahistidine-tag. J Med Chem 54:3817-3826
19. 3](+)-labeled affibody molecules. J Med Chem 56:4966-4974
20. Hopp TP, Woods KR (1981) Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci USA 78:3824-3828
21. Hosseinimehr SJ, Tolmachev V, Orlova A (2012) Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discov Today 17:1224-1232
22. Karamouzis MV, Papavassiliou AG (2012) Targeting insulin-like growth factor in breast cancer therapeutics. Crit Rev Oncol Hematol 84:8-17
23. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215-244
24. Kyte J, Doolittle RF (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol 157:105-132
25. LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195:127-137
26. Li J, Lundberg E, Vernet E, Larsson B, Höidén-Guthenberg I, Gräslund T (2010) Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor. Biotechnol Appl Biochem 55:99-109
27. Li P, Veldwijk MR, Zhang Q, Li ZB, Xu WC, Fu S (2013) Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells. BMC Cancer 13:297
28. Lindberg H, Hofström C, Altai M, Honorvar H, Wållberg H, Orlova A, Ståhl S, Gräslund T, Tolmachev V (2012) Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. Tumour Biol 33:641-651
29. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY (2010) Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584:2670-2680
30. Nygren PA (2008) Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 275:2668-2676
31. 3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. Eur J Nucl Med Mol Imaging 40:439-449
32. Ouban A, Muraca P, Yeatman T, Coppola D (2003) Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34(8):803-808
33. Pollak M (2012) The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 18:40-50
34. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518
35. Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6:1-12
36. Surinya KH, Forbes BE, Occhiodoro F, Booker GW, Francis GL, Siddle K, Wallace JC, Cosgrove LJ (2008) An investigation of the ligand binding properties and negative cooperativity of soluble insulin-like growth factor receptors. J Biol Chem 283:5355-5363
37. Tolmachev V, Friedman M, Sandström M, Eriksson TJ, Rosik D, Hodik M, Ståhl S, Frejd FY, Orlova A (2009) Affibody molecules for EGFR targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 50:274-283
38. Tolmachev V, Stone-Elander S, Orlova A (2010a) Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 11:992-1000
39. 3](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. Bioconjug Chem 21:2013-2022
40. Tolmachev V, Malmberg J, Hofström C, Abrahmsén L, Bergman T, Sjöberg A, Sandström M, Gräslund T, Orlova A (2012a) Imaging of insulin like growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551. J Nucl Med 53:90-97
41. Tolmachev V, Tran TA, Rosik D, Sjöberg A, Abrahmsén L, Orlova A (2012b) Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med 53:953-960
42. Tolmachev V, Varasteh Z, Honarvar H, Hosseinimehr SJ, Eriksson O, Jonasson P, Frejd FY, Abrahmsen L, Orlova A (2014) Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591. J Nucl Med 55:294-300
43. Tran T, Engfeldt T, Orlova A, Widström C, Bruskin A, Tolmachev V, Karlström AE (2007) In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules. Bioconjug Chem 18:549-558
44. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R, Glazer PM (1997) Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57:3079-3083
45. Turney BW, Kerr M, Chitnis MM, Lodhia K, Wang Y, Riedemann J, Rochester M, Protheroe AS, Brewster SF, Macaulay VM (2012) Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks. Radiother Oncol 103:402-409
46. Wållberg H, Orlova A, Altai M, Hosseinimehr SJ, Widström C, Malmberg J, Ståhl S, Tolmachev V (2011) Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J Nucl Med 52:461-469
47. Werner H, Bruchim I (2009) The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 115:58-71
48. Zuckier LS, Dohan O, Li Y, Chang C, Carrasco N, Dadachova E (2004) Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J Nucl Med 45:500-507